메뉴 건너뛰기
Archives of Dermatology
Volumn 143, Issue 4, 2007, Pages 545-546
Topical calcineurin inhibitors revisited [3]
Author keywords

[No Author keywords available]
Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; TACROLIMUS;
EID: 34247392323     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.4.545     Document Type: Letter
Times cited : (2)
References (7)
  • 1
    • 33748764373 scopus 로고    scopus 로고
    • Topical calcineurin inhibitors labeling: Putting the "box" in perspective
    • Stern RS. Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol. 2006;142:1233-1235.
    • (2006) Arch Dermatol , vol.142 , pp. 1233-1235
    • Stern, R.S.1
  • 2
    • 33646545065 scopus 로고    scopus 로고
    • Topical calcineurin inhibitors for atopic dermatitis: Balancing clinical benefit and possible risks
    • Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol. 2006;142:633-637.
    • (2006) Arch Dermatol , vol.142 , pp. 633-637
    • Qureshi, A.A.1    Fischer, M.A.2
  • 3
    • 34247360125 scopus 로고    scopus 로고
    • Committee on the Assessment of the US Drug Safety SystemBoard on Population Health and Public Health Practice. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: Institute of Medicine; 2006
    • Committee on the Assessment of the US Drug Safety SystemBoard on Population Health and Public Health Practice. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: Institute of Medicine; 2006.
  • 4
    • 34247354290 scopus 로고    scopus 로고
    • Department of Health and Human ServicesFood and Drug Administration Report on the performance of drug and biologics firms in conducting postmarketing commitment studies: availability, Accessed December 20, 2006
    • Department of Health and Human ServicesFood and Drug Administration Report on the performance of drug and biologics firms in conducting postmarketing commitment studies: availability. Http://www.fda.gov/OHRMS/ DOCKETS/98fr/E6-3019.pdf. Accessed December 20, 2006.
  • 5
    • 33750343053 scopus 로고    scopus 로고
    • Blueprint for a stronger Food and Drug Administration
    • Curfman GD, Morrissey S, Drazen JM. Blueprint for a stronger Food and Drug Administration. N Engl J Med. 2006;355:1821.
    • (2006) N Engl J Med , vol.355 , pp. 1821
    • Curfman, G.D.1    Morrissey, S.2    Drazen, J.M.3
  • 6
    • 33750284204 scopus 로고    scopus 로고
    • Protecting the health of the public-Institute of Medicine recommendations on drug safety
    • Psaty BM, Burke SP. Protecting the health of the public-Institute of Medicine recommendations on drug safety. N Engl J Med. 2006;355:1753-1755.
    • (2006) N Engl J Med , vol.355 , pp. 1753-1755
    • Psaty, B.M.1    Burke, S.P.2
  • 7
    • 34247375316 scopus 로고    scopus 로고
    • National Eczema Association policy for requests for proposals
    • Cooper K. National Eczema Association policy for requests for proposals. Arch Dermatol. 2007;143:545-546.
    • (2007) Arch Dermatol , vol.143 , pp. 545-546
    • Cooper, K.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.